Complete Filing Data
Aspire Biopharma Holdings, Inc. reported Stockholders Equity of -$6.38 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Aspire Biopharma Holdings, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | -$24.5M | -$1.3M | $4.5M | $3.3M | -$25.5K |
| Operating Expenses | $19.4M | $1.2M | $1.3M | $976.3K | $25.5K |
| General And Administrative Expense | $17.6M | $940.4K | $1.3M | $976.3K | $25.5K |
| Nonoperating Income Expense | -$5.1M | -$98.0K | $5.8M | $4.3M | |
| Research And Development Expense | $923.9K | $144.4K | |||
| Selling And Marketing Expense | $789.8K | $126.1K | |||
| Interest Expense Debt | $891.6K | $9.0K | |||
| Operating Income Loss | -$19.4M | -$1.2M | |||
| Revenue From Contract With Customer Including Assessed Tax | $6.2K | ||||
| Cost Of Goods And Services Sold | $6.3K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$1.9M | -$2.0M | -$15.9M | -$765.7K | -$216.3K | -$96.9K | -$231.0K | -$69.3K | $1.8M | $2.9M | $1.1M | $120.7K | -$87.8K | -$15.3K | -$2.4K | -$7.0K |
| Operating Expenses | $1.1M | $799.9K | $15.6M | $215.3K | $96.9K | $231.0K | $324.7K | $288.2K | $324.6K | $255.3K | $297.8K | $109.2K | $15.3K | $2.4K | $7.7K | |
| General And Administrative Expense | $513.0K | $395.7K | $15.1M | $191.6K | $86.4K | $132.8K | $324.7K | $288.2K | $324.6K | $255.3K | $297.8K | $109.2K | $15.3K | $2.4K | $7.7K | |
| Nonoperating Income Expense | -$705.0K | -$1.2M | -$384.8K | $93.8K | -$101.2K | $55.6K | $255.5K | $2.1M | $3.2M | $1.3M | $418.5K | $21.4K | ||||
| Research And Development Expense | $207.9K | $352.9K | $263.1K | $7.0K | $10.5K | $10.5K | ||||||||||
| Selling And Marketing Expense | $425.5K | $51.3K | $219.8K | $16.7K | $87.7K | |||||||||||
| Interest Expense Debt | $289.9K | $183.3K | ||||||||||||||
| Operating Income Loss | -$1.1M | -$215.3K | ||||||||||||||
| Revenue From Contract With Customer Including Assessed Tax | $1.9K | |||||||||||||||
| Cost Of Goods And Services Sold | $1.1K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity | -$6.4M | -$1.5M | -$487.9K | -$9.9M | -$475.00 |
| Temporary Equity Accretion To Redemption Value Adjustment | |||||
| Retained Earnings Accumulated Deficit | -$27.3M | -$2.8M | -$11.3M | -$9.9M | -$25.5K |
| Liabilities Current | $7.6M | $1.7M | $403.3K | $303.3K | $293.7K |
| Liabilities And Stockholders Equity | $1.3M | $148.0K | $20.0M | $300.2M | $293.2K |
| Liabilities | $7.7M | $1.7M | $403.3K | $11.1M | $293.7K |
| Assets Current | $1.3M | $148.0K | $81.2K | $1.1M | $293.2K |
| Assets | $1.3M | $148.0K | $20.0M | $300.2M | $293.2K |
| Other Liabilities Current | $353.7K | $111.0K | $238.9K | $122.7K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.0M | -$7.5K | -$497.3K | $497.3K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.0M | $3.6K | $11.2K | $497.3K | |
| Temporary Equity Carrying Amount Attributable To Parent | $6.7M | $19.9M | |||
| Accounts Payable And Accrued Liabilities Current | $1.0M | $152.0K | $180.6K | $273.00 | |
| Prepaid Expense And Other Assets Current | $55.1K | $144.4K | $81.2K | $600.5K | |
| Assets Held In Trust Noncurrent | $6.7M | $19.9M | $299.0M | ||
| Deferred Offering Costs Noncurrent | $10.8M | $10.8M | |||
| Deferred Underwriting Commissions Payable Charged To Additional Paid In Capital | -$10.8M | $10.8M | |||
| Notes And Loans Payable Current | $465.7K | $12.4K | |||
| Accounts Payable Current | $1.0M | $310.2K | |||
| Initial Value Of Class Common Stock Subject To Possible Redemption | $294.7M | ||||
| Common Stock Value | $353.00 | $69.00 | |||
| Other Receivables | $36.5K | ||||
| Repayments Of Related Party Debt | $252.9K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$11.5M | -$9.6M | -$8.0M | -$774.4K | -$558.1K | -$489.7K | -$63.0K | $261.8K | -$10.3M | -$9.6M | -$9.4M | -$9.0M | $280.00 | $15.6K | $18.0K | |
| Temporary Equity Accretion To Redemption Value Adjustment | -$76.7K | -$169.9K | -$234.9K | -$255.5K | -$2.1M | -$3.2M | -$1.3M | -$439.9K | -$28.9M | |||||||
| Retained Earnings Accumulated Deficit | -$22.6M | -$20.7M | -$18.7M | -$15.4M | -$14.8M | -$14.0M | -$10.9M | -$10.6M | -$10.3M | -$9.6M | -$9.4M | -$9.1M | ||||
| Liabilities Current | $13.9M | $10.6M | $8.9M | $6.6M | $6.2M | $2.6M | $316.3K | $284.4K | $356.4K | $188.7K | $146.5K | $51.8K | ||||
| Liabilities And Stockholders Equity | $2.4M | $989.4K | $2.0M | $6.7M | $6.9M | $20.2M | $19.9M | $20.6M | $303.1M | $297.8M | $296.7M | $296.5M | ||||
| Liabilities | $13.9M | $10.6M | $8.9M | $6.6M | $6.2M | $2.6M | $316.3K | $284.4K | $11.2M | $11.0M | $11.0M | $10.9M | ||||
| Assets Current | $2.4M | $989.4K | $2.0M | $61.8K | $343.0K | $65.6K | $253.4K | $546.1K | $906.5K | $1.1M | $1.2M | $1.3M | ||||
| Assets | $2.4M | $989.4K | $2.0M | $6.7M | $6.9M | $20.2M | $19.9M | $20.6M | $303.1M | $297.8M | $296.7M | $296.5M | ||||
| Other Liabilities Current | $353.7K | $328.9K | $298.9K | $268.9K | $211.9K | $182.7K | ||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.3M | $36.1K | -$182.1K | $618.1K | ||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $1.9M | $206.2K | $1.3M | $16.5K | $19.6K | $47.3K | $280.00 | $125.2K | $315.2K | $533.1K | $579.8K | $618.1K | ||||
| Temporary Equity Carrying Amount Attributable To Parent | $6.6M | $6.5M | $20.1M | $19.6M | $20.0M | $302.2M | $299.0M | $296.5M | $295.1M | $294.7M | ||||||
| Accounts Payable And Accrued Liabilities Current | $903.7K | $584.1K | $365.0K | $104.4K | $101.7K | $203.7K | $96.0K | $83.8K | $19.1K | |||||||
| Prepaid Expense And Other Assets Current | $419.4K | $783.2K | $619.0K | $36.8K | $43.1K | $65.6K | $253.1K | $420.9K | $591.3K | $613.4K | $629.1K | $644.9K | ||||
| Assets Held In Trust Noncurrent | $6.6M | $6.5M | $20.1M | $19.6M | $20.0M | $302.2M | $296.5M | $295.1M | $294.7M | |||||||
| Deferred Offering Costs Noncurrent | $10.8M | $10.8M | $10.8M | $10.8M | ||||||||||||
| Deferred Underwriting Commissions Payable Charged To Additional Paid In Capital | $10.8M | |||||||||||||||
| Notes And Loans Payable Current | $436.3K | $427.8K | $217.2K | |||||||||||||
| Accounts Payable Current | $1.1M | $1.4M | $1.4M | |||||||||||||
| Initial Value Of Class Common Stock Subject To Possible Redemption | $294.7M | |||||||||||||||
| Common Stock Value | $5.0K | $5.0K | $4.9K | |||||||||||||
| Other Receivables | $25.0K | $299.9K | ||||||||||||||
| Repayments Of Related Party Debt |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Share-Based Compensation * | $14.1M | $0.00 | |||
| Net Cash Provided By Used In Operating Activities | -$4.9M | -$265.2K | -$653.1K | -$1.4M | -$238.6K |
| Net Cash Provided By Used In Financing Activities | $5.9M | $257.6K | -$284.8M | $296.6M | $238.6K |
| Increase Decrease In Prepaid Expense | -$71.9K | -$599.4K | $680.7K | ||
| Net Cash Provided By Used In Investing Activities | $13.8M | $284.9M | -$294.7M | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $878.6K | -$28.6K | $125.5K | $273.00 | |
| Increase Decrease In Due To Affiliates Current | $120.0K | $116.3K | $122.7K | ||
| Proceeds From Cash Withdrawn From Trust Account In Connection With Redemptions | $13.8M | $284.9M | |||
| Payments For Repurchase Of Common Stock | $13.8M | $284.9M | |||
| Proceeds From Issuance Of Common Stock | $2.5M | $257.6K | |||
| Increase Decrease In Accounts Payable | -$323.8K | $247.8K | |||
| Proceeds From Related Party Debt | $343.4K | $155.8K | $238.6K | ||
| Proceeds From Payments For Other Financing Activities | $265.8K | $1.7M | |||
| Increase Decrease In Due From Related Parties | $36.5K | ||||
| Payments Of Stock Issuance Costs | $298.5K | ||||
| Proceeds From Issuance Of Warrants | $14.6M | ||||
| Payments To Acquire Restricted Investments | $294.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q1 2025 | Q3 2024 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $0.00 | $14.1M | $0.00 | ||||
| Net Cash Provided By Used In Operating Activities | -$1.8M | -$193.0K | -$182.1K | -$1.3M | -$166.0K | ||
| Net Cash Provided By Used In Financing Activities | $3.1M | $229.1K | $296.6M | ||||
| Increase Decrease In Prepaid Expense | $389.6K | -$5.0K | -$89.4K | $1.2M | |||
| Net Cash Provided By Used In Investing Activities | -$294.7M | $166.0K | |||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $213.0K | $23.1K | -$36.0K | ||||
| Increase Decrease In Due To Affiliates Current | $30.0K | $30.0K | $32.7K | ||||
| Proceeds From Cash Withdrawn From Trust Account In Connection With Redemptions | |||||||
| Payments For Repurchase Of Common Stock | |||||||
| Proceeds From Issuance Of Common Stock | $229.1K | ||||||
| Increase Decrease In Accounts Payable | $1.1M | -$41.8K | |||||
| Proceeds From Related Party Debt | $264.0K | ||||||
| Proceeds From Payments For Other Financing Activities | $265.8K | ||||||
| Increase Decrease In Due From Related Parties | $1.0M | -$74.8K | |||||
| Payments Of Stock Issuance Costs | $298.5K | ||||||
| Proceeds From Issuance Of Warrants | $14.6M | ||||||
| Payments To Acquire Restricted Investments |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 5.0M | 5.0M | 5.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 3.5M | 690.0K | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Shares Outstanding Basic | 1.5M | 689.9K | |||
| Weighted Average Number Of Diluted Shares Outstanding | 1.5M | 689.9K | |||
| Earnings Per Share Diluted | $-16.38 | $-1.90 | |||
| Earnings Per Share Basic | |||||
| Common Stock Shares Issued | 3.5M | 690.0K | |||
| Common Stock Shares Authorized | 490.0M | 490.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 49.5M | 49.5M | 48.9M | |||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |||||||||
| Weighted Average Number Of Shares Outstanding Basic | 49.5M | 27.6M | ||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 49.5M | 27.6M | ||||||||||
| Earnings Per Share Diluted | $-0.04 | $-0.01 | ||||||||||
| Earnings Per Share Basic | $-0.04 | $-0.01 | ||||||||||
| Common Stock Shares Issued | 49.5M | 49.5M | 48.9M | |||||||||
| Common Stock Shares Authorized | 490.0M | 490.0M | 490.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Investment Income Interest | $548.7K | $5.8M | $4.3M | ||
| Remeasurement Of Ordinary Shares To Redemption Value | 548.7K | 5.8M | 33.2M | ||
| Additional Paid In Capital | $20.9M | $1.2M | $11.0M | $24.3K | |
| Adjustments To Additional Paid In Capital Stockholder Non Redemption Agreements | -$784.3K | -$118.3K | |||
| Adjustments To Additional Paid In Capital Contribution Stock Non Redemption Agreements | $784.3K | $118.3K | |||
| Sponsor Shares Contributed For No Redemption Of Shares | 784.3K | 118.3K | |||
| Adjustments To Additional Paid In Capital Face Value Of Convertible Note In Excess Of Fair Value | $315.5K | $152.4K | |||
| Adjustments To Additional Paid In Capital Other | $10.8M | ||||
| Subscription Agreement Loan | $1.5M | $13.8M | |||
| Conversion Of Stock Amount Issued1 | $719.00 | ||||
| Adjustments To Additional Paid In Capital Issuance Of Subscription | |||||
| Prepaid Expense Noncurrent | $80.2K | ||||
| Adjustments To Additional Paid In Capital Warrant Issued | $14.6M | ||||
| Stock Issued During Period Value New Issues | $25.0K | ||||
| Change In Fair Value Of Convertible Note | |||||
| Derivative Gain Loss On Derivative Net | $3.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment Income Interest | $76.7K | $169.9K | $234.9K | $255.5K | $2.1M | $3.2M | $1.3M | $418.5K | $21.4K | ||||
| Remeasurement Of Ordinary Shares To Redemption Value | 234.9K | 3.2M | |||||||||||
| Additional Paid In Capital | $11.1M | $11.1M | $11.8M | $8.9M | $8.9M | $11.4M | $10.8M | $10.8M | |||||
| Adjustments To Additional Paid In Capital Stockholder Non Redemption Agreements | -$784.3K | -$118.3K | |||||||||||
| Adjustments To Additional Paid In Capital Contribution Stock Non Redemption Agreements | $784.3K | $118.3K | |||||||||||
| Sponsor Shares Contributed For No Redemption Of Shares | |||||||||||||
| Adjustments To Additional Paid In Capital Face Value Of Convertible Note In Excess Of Fair Value | $27.0K | $242.5K | |||||||||||
| Adjustments To Additional Paid In Capital Other | $10.8M | ||||||||||||
| Subscription Agreement Loan | $1.5M | $2.0M | $1.9M | $4.9M | $4.9M | ||||||||
| Conversion Of Stock Amount Issued1 | |||||||||||||
| Adjustments To Additional Paid In Capital Issuance Of Subscription | -$2.6M | $213.8K | |||||||||||
| Prepaid Expense Noncurrent | $230.8K | $381.5K | $530.5K | ||||||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $14.6M | ||||||||||||
| Stock Issued During Period Value New Issues | $28.6K | $229.1K | $25.0K | ||||||||||
| Change In Fair Value Of Convertible Note | $8.5K | $208.2K | |||||||||||
| Derivative Gain Loss On Derivative Net | $775.1K | -$289.4K | -$94.9K |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.